NCT02285439 2025-10-07
Study of MEK162 for Children With Low-Grade Gliomas
Children's Hospital Los Angeles
Phase 1/2 Completed
Clinical Trials
10 trialsNCT03106415 2025-06-27
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
Mayo Clinic
Phase 1/2 Completed
NCT04720976 2025-04-11
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Allist Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04494958 2025-03-24
PALBOBIN
Fundacion Oncosur
Phase 1/2 Completed
NCT05340621 2025-03-07
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
OnKure, Inc.
Phase 1/2 Completed
NCT03843775 2024-10-21
A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01543698 2024-03-13
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
Pfizer
Phase 1/2 Completed
NCT01927341 2021-02-18
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
Pfizer
Phase 1/2 Completed
NCT02902042 2021-02-16
IMMU-TARGET
University Hospital, Essen
Phase 1/2 Completed
NCT02773459 2019-09-30
MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
Seoul National University Hospital
Phase 1/2 Completed